{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T22:28:49Z","timestamp":1785018529229,"version":"3.55.0"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2022,10,15]],"date-time":"2022-10-15T00:00:00Z","timestamp":1665792000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Tofacitinib is an oral small molecule Janus kinase inhibitor for the treatment of ulcerative colitis. We report health-related quality of life (HRQoL) outcomes in patients with ulcerative colitis in the phase 3 open-label, long-term extension study, OCTAVE Open.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The Inflammatory Bowel Disease Questionnaire (IBDQ), EuroQoL-5 Dimensions Health Questionnaire, and 36-Item Short Form Survey scores were analyzed up to month (M) 72 in 4 subpopulations: patients in remission at baseline (maintenance remitters) assigned tofacitinib 5 mg twice daily and patients not in remission at baseline (maintenance nonremitters, maintenance treatment failures, and induction nonresponders [IndNRs]) assigned tofacitinib 10 mg twice daily in OCTAVE Open. Data were analyzed overall and stratified by corticosteroid use at baseline, prior tumor necrosis factor inhibitor failure, and prior immunosuppressant failure.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among maintenance remitters and nonremitters, HRQoL outcomes were maintained up to M72: 80.0% and 100.0% of patients had an IBDQ total score \u2265170, respectively. At baseline, 7.4% of maintenance treatment failures had an IBDQ total score \u2265170, and this increased to 54.3% and 75.0% at M2 and M72, respectively. Corresponding values for IndNRs were 22.6%, 51.0%, and 86.0%. HRQoL outcomes were independent of treatment history. Among patients not in remission at baseline, improvement in EuroQoL-5 Dimensions Health Questionnaire and 36-Item Short Form Survey scores was maintained or achieved by M2, and steady to M72 or M33, with maintenance treatment failures and IndNR subpopulations undergoing the biggest improvements from baseline.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>A continued favorable impact on HRQoL was revealed with long-term tofacitinib treatment in OCTAVE Open, regardless of baseline remission status or treatment history. (ClinicalTrials.gov; number: NCT01470612).<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ibd\/izac222","type":"journal-article","created":{"date-parts":[[2022,10,15]],"date-time":"2022-10-15T15:46:45Z","timestamp":1665848805000},"page":"1370-1379","source":"Crossref","is-referenced-by-count":2,"title":["Health-Related Quality of Life Outcomes With Tofacitinib Treatment in Patients With Ulcerative Colitis in the Open-Label Extension Study, OCTAVE Open"],"prefix":"10.1093","volume":"29","author":[{"given":"Luc","family":"Biedermann","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, University Hospital Z\u00fcrich , Z\u00fcrich , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marla C","family":"Dubinsky","sequence":"additional","affiliation":[{"name":"Susan and Leonard Feinstein IBD Center, Icahn School of Medicine at Mount Sinai , New York, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9verine","family":"Vermeire","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, University Hospitals Leuven , Leuven , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0064-698X","authenticated-orcid":false,"given":"Marc","family":"Fellmann","sequence":"additional","affiliation":[{"name":"Pfizer Switzerland AG , Z\u00fcrich , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Gardiner","sequence":"additional","affiliation":[{"name":"Pfizer Inc , New York, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Hur","sequence":"additional","affiliation":[{"name":"Pfizer Inc , New York, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajiv","family":"Mundayat","sequence":"additional","affiliation":[{"name":"Pfizer Inc , New York, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Pan\u00e9s","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hospital Cl\u00ednic de Barcelona, August Pi i Sunyer Biomedical Research Institute, Centro de Investigaci\u00f3n Biom\u00e9dica en Red Enfermedades Hep\u00e1ticas y Digestivas , Barcelona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David T","family":"Rubin","sequence":"additional","affiliation":[{"name":"University of Chicago Medicine Inflammatory Bowel Disease Center , Chicago, IL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,10,15]]},"reference":[{"key":"2023090112002205200_CIT0001","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(16)32126-2","article-title":"Ulcerative colitis","volume":"389","author":"Ungaro","year":"2017","journal-title":"Lancet."},{"key":"2023090112002205200_CIT0002","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1093\/ibd\/izab016","article-title":"Ulcerative Colitis Narrative Global survey findings: the impact of living with ulcerative colitis - a patients\u2019 and physicians\u2019 view","volume":"27","author":"Dubinsky","year":"2021","journal-title":"Inflamm Bowel Dis."},{"key":"2023090112002205200_CIT0003","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1097\/MIB.0000000000000620","article-title":"Controversies revisited: a systematic review of the comorbidity of depression and anxiety with inflammatory bowel diseases","volume":"22","author":"Mikocka-Walus","year":"2016","journal-title":"Inflamm Bowel Dis."},{"key":"2023090112002205200_CIT0004","first-page":"111","article-title":"Inflammatory bowel disease and anxiety: links, risks, and challenges faced","volume":"8","author":"Bannaga","year":"2015","journal-title":"Clin Exp Gastroenterol."},{"key":"2023090112002205200_CIT0005","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/ecco-jcc\/jjx133","article-title":"Tofacitinib in patients with ulcerative colitis: health-related quality of life in Phase 3 randomised controlled induction and maintenance studies","volume":"12","author":"Pan\u00e9s","year":"2018","journal-title":"J Crohns Colitis."},{"key":"2023090112002205200_CIT0006","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1111\/j.1572-0241.2007.01094.x","article-title":"The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients","volume":"102","author":"Feagan","year":"2007","journal-title":"Am J Gastroenterol."},{"key":"2023090112002205200_CIT0007","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1093\/ecco-jcc\/jjv002","article-title":"Systematic review of health-related quality of life measures for inflammatory bowel disease","volume":"9","author":"Alrubaiy","year":"2015","journal-title":"J Crohns Colitis."},{"key":"2023090112002205200_CIT0008","author":"EuroQol Research Foundation"},{"key":"2023090112002205200_CIT0009","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection","volume":"30","author":"Ware","year":"1992","journal-title":"Med Care."},{"key":"2023090112002205200_CIT0010","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology."},{"key":"2023090112002205200_CIT0011","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N Engl J Med."},{"key":"2023090112002205200_CIT0012","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/apt.16712","article-title":"Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open-label, long-term extension study with up to 7.0 years of treatment","volume":"55","author":"Sandborn","year":"2022","journal-title":"Aliment Pharmacol Ther."},{"key":"2023090112002205200_CIT0013","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/0016-5085(89)90905-0","article-title":"A new measure of health status for clinical trials in inflammatory bowel disease","volume":"96","author":"Guyatt","year":"1989","journal-title":"Gastroenterology."},{"key":"2023090112002205200_CIT0014","volume-title":"User\u2019s Manual for the SF-36v2\u00ae Health Survey","author":"Ware","year":"2007","edition":"2"},{"key":"2023090112002205200_CIT0015","author":"U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER)"},{"key":"2023090112002205200_CIT0016","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1093\/ibd\/izaa193","article-title":"Tofacitinib in patients with ulcerative colitis: inflammatory bowel disease questionnaire items in Phase 3 randomized controlled induction studies","volume":"27","author":"Dubinsky","year":"2021","journal-title":"Inflamm Bowel Dis."},{"issue":"9","key":"2023090112002205200_CIT0017","first-page":"CD008655","article-title":"The impact of biological interventions for ulcerative colitis on health-related quality of life","author":"LeBlanc","year":"2015;(","journal-title":"Cochrane Database Syst Rev."},{"key":"2023090112002205200_CIT0018","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1111\/apt.16060","article-title":"Long-term safety of vedolizumab for inflammatory bowel disease","volume":"52","author":"Loftus","year":"2020","journal-title":"Aliment Pharmacol Ther."},{"key":"2023090112002205200_CIT0019","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/ibd.21697","article-title":"Long-term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and -2 extension studies","volume":"18","author":"Reinisch","year":"2012","journal-title":"Inflamm Bowel Dis."},{"issue":"suppl_1","key":"2023090112002205200_CIT0020","doi-asserted-by":"crossref","first-page":"i538","DOI":"10.1093\/ecco-jcc\/jjab232.733","article-title":"Efficacy and safety of tofacitinib in ulcerative colitis patients with extraintestinal manifestations in OCTAVE Open (P607)","volume":"16","author":"Rubin","year":"2022","journal-title":"J Crohns Colitis"},{"key":"2023090112002205200_CIT0021","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.cgh.2020.10.004","article-title":"Maintenance of remission with tofacitinib therapy in patients with ulcerative colitis","volume":"20","author":"Colombel","year":"2022","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2023090112002205200_CIT0022","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/apt.15555","article-title":"Efficacy and safety of tofacitinib dose de-escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open","volume":"51","author":"Sands","year":"2020","journal-title":"Aliment Pharmacol Ther."},{"key":"2023090112002205200_CIT0023","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1016\/j.cgh.2020.10.038","article-title":"Efficacy and safety of extended induction with tofacitinib for the treatment of ulcerative colitis","volume":"20","author":"Sandborn","year":"2022","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2023090112002205200_CIT0024","doi-asserted-by":"crossref","first-page":"e0165435","DOI":"10.1371\/journal.pone.0165435","article-title":"Systematic review with network meta-analysis: comparative efficacy of biologics in the treatment of moderately to severely active ulcerative colitis","volume":"11","author":"Vickers","year":"2016","journal-title":"PLoS One."},{"key":"2023090112002205200_CIT0025","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/apt.14422","article-title":"Systematic review with network meta-analysis: first- and second-line pharmacotherapy for moderate-severe ulcerative colitis","volume":"47","author":"Singh","year":"2018","journal-title":"Aliment Pharmacol Ther."},{"key":"2023090112002205200_CIT0026","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1093\/ecco-jcc\/jjaa249","article-title":"Outcomes of tofacitinib dose reduction in patients with ulcerative colitis in stable remission from the randomised RIVETING trial","volume":"15","author":"Vermeire","year":"2021","journal-title":"J Crohns Colitis."}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/advance-article-pdf\/doi\/10.1093\/ibd\/izac222\/46539355\/izac222.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/29\/9\/1370\/51317471\/izac222.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/29\/9\/1370\/51317471\/izac222.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T13:01:55Z","timestamp":1693573315000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/29\/9\/1370\/6761656"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,15]]},"references-count":26,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,10,15]]},"published-print":{"date-parts":[[2023,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izac222","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,9,1]]},"published":{"date-parts":[[2022,10,15]]}}}